The GMP (Good Manufacturing Practices) Certification of our antibiotics, antifungals, and volume expanders assures excellent levels of quality, which are used to treat challenging disease conditions like sepsis, life-threatening bacterial & fungal infection, burns and trauma. Patients who are immunocompromised or critically unwell frequently develop invasive fungal infections (IFIs), which have significant rates of morbidity and mortality. With a high mortality rate of over 44%, Candida bloodstream infection (candidemia) is a condition, should be taken seriously for patients admitted in intensive care units (ICUs). Invasive Mould Infections (IMI) is also linked to a high mortality rate of almost 65% in India. For patients to survive, it is essential to begin the right antifungal treatment as soon as possible. Amphotericin B is a medication may save lives when used at right dose and right time to treat severe systemic fungi infections.
The World Health Organization (WHO) classifies âBurnsâ as a global public health hazard, accounting to an estimated 180000 deaths annually, with India accounting for over 1 million of that number. People who have experienced severe burns may face ongoing emotional and physical difficulties due to the resulting physical and mental implications, and societal stigma.
Our Novel enzymatic debridement agent (concentrate of proteolytic enzymes enriched in bromelain) is a topically administered biological product that enzymatically removes nonviable burn tissue, or eschar, in patients with deep partial and full-thickness thermal burns within a few hours of application, without harming viable tissue.
Reversal of Oral Anticoagulant Agent (OCA) is required when a patient receiving OACs develops bleeding complications or needs urgent surgery. This can be achieved either by replacing the missing factors under Vitamin K Antagonists (VKA) treatment using blood products or by eliminating or compensating the inhibiting function of the direct-acting OCA (DOAC). The Reversal agents for VKAs include four-factor prothrombin complex concentrate (4F-PCC) and fresh frozen plasma (FFP).
Our product is a plasma-derived, virally inactivated Human 4F-PCC containing coagulation factors II, VII, IX, and X. It also contains the naturally occurring anticoagulants protein C and protein S. It is primarily used for the treatment of bleeding and peri-operative prophylaxis of bleeding in acquired deficiency of the prothrombin complex coagulation factors, such as deficiency caused by treatment with VKAs. It is also indicated in the management of bleeding or during surgery in patients with congenital deficiencies of vitamin K-dependent coagulation factors.
